Next-Gen SERD Cuts Breast Cancer Recurrence Risk by 30% in Trial
✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source
A next-generation selective estrogen receptor degrader (SERD) has been found to reduce the risk of breast cancer recurrence. The reduction in risk is reported to be 30 percent in a trial. The results suggest a potential benefit of this treatment in reducing breast cancer recurrence.